2020
Fedratinib hydrochloride to treat intermediate-2 or high-risk primary or secondary myelofibrosis.
Schiffer M, Kowalski A, Zhao J, Bewersdorf JP, Lewis RS, Zeidan AM. Fedratinib hydrochloride to treat intermediate-2 or high-risk primary or secondary myelofibrosis. Drugs Of Today 2020, 56: 755-768. PMID: 33332482, DOI: 10.1358/dot.2020.56.12.3230206.Peer-Reviewed Original ResearchConceptsSecondary myelofibrosisClinical holdSelective Janus kinase 2 inhibitorNovel oral agentsCommon adverse effectsClinical trial dataFurther drug developmentGastrointestinal symptomsLiver transaminasesOral agentsSymptom burdenJanus kinase 2 inhibitorDrug AdministrationMyeloproliferative neoplasmsTrial dataU.S. FoodAdverse effectsKinase 2 inhibitorPhase IIDrug developmentMyelofibrosisSignificant reductionFurther investigationFedratinibSplenomegaly
2019
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
Bewersdorf JP, Jaszczur SM, Afifi S, Zhao JC, Zeidan AM. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis. Cancer Management And Research 2019, 11: 10777-10790. PMID: 31920387, PMCID: PMC6935287, DOI: 10.2147/cmar.s212559.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsTreatment optionsFavorable risk/benefit ratioRisk/benefit ratioEmergent treatment optionsHigh-risk patientsPhase II trialMain side effectsFuture treatment optionsBone marrow fibrosisGastrointestinal symptomsII trialLiver transaminasesAdverse eventsSymptom burdenOngoing trialsJAK1/2 inhibitorMF patientsMarrow fibrosisClinical trialsSecondary myelofibrosisBox warningSelective JAK2 inhibitorExtramedullary hematopoiesisSecond drugThiamine levels